PLOS ONE | DOI:10.1371/journal.pone.0133869 July 28, 2015, p.1-16
Monitoring of implementation of collaborative TB/HIV activities and evaluation of impact is critically important. This requires efficient monitoring and evaluation system so as to establish accountability mechanisms between programmes, the population they serve, and donors. The Guide to monitoring a...nd evaluation for collaborative TB/HIV activities will facilitate this process. The first version of the guide was developed in 2004 placing collaborative TB/HIV activities as integral part of national TB/HIV response. It was revised in 2009 to harmonize the approaches and indicators for monitoring and evaluation across key stakeholders. The current revision builds upon remarkable progress in implementation of collaborative TB/HIV activities and aims to strengthen the implementation further through improved quality of data.
more
Time for recognition of lay counsellors
Accessed November 2017
Health Evidence Network synthesis report 53
WHO/HTM/TB/2007.384a
“TB is too often a death sentence for people with AIDS.
It does not have to be this way.”
-Nelson Mandela, International conference on HIV /AIDS, Bangkok, Thailand, July 2004
Collection of country-level good practices
This guidance is intended for use in developing standalone TB strategic plans, or TB interventions as part of multidisease or health sector plans. It describes key considerations and steps for strategic planning for TB in line with the World Health Organization’s End TB strategy, and the proposed ...structure of the NSP. The target audience of this publication are all stakeholders involved in national strategic planning for TB (e.g., ministry of health, other government ministries, private sector, civil society, affected communities, academic and research institutions, and technical and funding partners).
The current document is an update to the 2015 Toolkit to develop a national strategic plan for TB prevention, care and control.
more
First Edition, July 2009
Trainers’ Manual
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Discussion paper initially prepared in April 2015 to facilitate feedback, and finalized after the
June 2015 meeting of WHO’s Strategic and Technical Advisory Group for TB (STAG-TB).
A manual for health managers
PLoS ONE 9(1): e87262. doi:10.1371/journal.pone.0087262